MEASLES VACCINATION USING MVVAC2

这个子项目是利用资源的许多研究子项目之一 由NIH/NCRR资助的中心拨款提供。次级项目的主要支助 子项目的主要研究者可能是由其他来源提供的， 包括其它NIH来源。 为子项目列出的总成本可能 代表子项目使用的中心基础设施的估计数量， NCRR赠款不直接向子项目或子项目工作人员提供资金。 麻疹病毒（MV）是一种天然的人类病原体，但亚洲猕猴和其他一些非人灵长类动物是易感的。麻疹的发病机制在恒河猴和食蟹猴中非常接近。MV感染和疾病，具有显著的死亡率，可以在灵长类动物群体中广泛传播。包括CNPRC在内的几个灵长类动物中心已经使用定期的年度麻疹疫苗接种来保护易感物种免受人类引入的麻疹。这项政策多年来一直有效;但目前，已经成功使用的麻疹或犬瘟热疫苗已被撤出市场。在过去3年中，CNPRC没有对灵长类动物进行麻疹疫苗接种。我们已经测试了一种分子克隆麻疹疫苗株，它来自一瓶Moraten株麻疹疫苗，我们将其命名为MVvac 2。该病毒感染恒河猴的致病性减弱，并且保护猴子免受致病性MV攻击。该疫苗病毒可在Vero细胞中生长至105 - 106组织培养感染剂量/ml的滴度，因此它将是用于灵长类动物群体管理的实用疫苗。疫苗储备液可以大量生产（100剂），并以等分试样冷冻保存，使用前立即解冻。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Measles virus (MV) is a natural human pathogen, but several species of Asian macaque and some other nonhuman primates are susceptible. The pathogenesis of measles is modeled very closely in rhesus and cynomolgus macaques. MV infection and disease, with significant mortality, can be widespread in primate colonies. Several primate centers, including the CNPRC, have used regular, annual measles vaccination to protect susceptible species from measles introduced by humans. This policy has been effective for many years; but currently, the measles or canine distemper vaccines that have been used successfully have been taken off the market. There has been no measles vaccination of primates at the CNPRC for the last 3 years. We have tested a molecularly cloned measles vaccine strain, derived from a vial of the Moraten strain measles vaccine, which we designate MVvac2. This virus infects rhesus monkeys with an attenuated pathogenesis, and the monkeys are protected from pathogenic MV challenge. This vaccine virus can be grown in Vero cells to titers of 105 - 106 tissue culture infectious doses per ml, thus it would be a practical vaccine for primate colony management. Vaccine stocks could be produced in large volume ( 100 doses) and cryopreserevd in aliquots that would be thawed immediately before use.